会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PULSE OXIMETRY METHODS, DEVICES AND SYSTEMS
    • WO2021069729A1
    • 2021-04-15
    • PCT/EP2020/078516
    • 2020-10-09
    • LIFE METER SRL
    • DE BENEDETTO, FernandoAVENTAGGIATO, MatteoRAIMONDI, MarcoVISCONTI, Alberto
    • A61B5/1455
    • There is provided a method of taking pulse oximetry measurements, the method comprising: providing a calibration pulse-oximeter adapted to estimate one or more first, reference SpO2 values from a first, reference PPG signal measured by the pulse-oximeter on a first, reference area of the human body; and, using the same or a different calibration pulse-oximeter, estimating one or more second SpO2 values from a second PPG signal measured by said same or different calibration pulse-oximeter on a second, target area of the human body. At this point, a calibration parameter or calibration function is calculated on the basis of the one or more first, reference SpO2 values and the second SpO2 values. Then, using a measurement pulse-oximeter, a plurality of third SpO2 values is measured from the second PPG signal on the second, target area of the human body and the resulting values are calibrated using said calibration parameter or function. In this manner, measurements taken for example with a bracelet-type pulse oximeter on an area relatively poorly perfused with blood can be improved on the basis of calibration measurements taken on an area better perfused with blood. A manner of further improving such measurements is by providing multiple sensing units on the measurement pulse oximeter, which can each be calibrated against the reference pulse oximeter.
    • 8. 发明申请
    • PULSED ELECTROMAGNETIC FIELD DEVICE AND METHOD OF TREATMENT
    • WO2019175289A1
    • 2019-09-19
    • PCT/EP2019/056359
    • 2019-03-13
    • H A INVESTORS LIMITED
    • MAYO, John CharlesHUNT, Thomas
    • A61N1/40A61N1/32A61N1/36A61N1/02A61N1/06
    • A method including use of physiological data from an individual to determine the emission pattern of a pulsed electromagnetic field "PEMF" so that the pattern is personalised to the physiological needs of the individual. The PEMF emission pattern may have a parameter which is calculated based on the physiological data from the individual to cause the physiological state of the individual to be altered or maintained beneficially. The physiological state of the individual can be moved to or towards (or maintained at) an ideal state more effectively than if the physiological data from the individual is not used to determine the PEMF emission pattern. The method may include calculating the PEMF emission pattern based on both idealised data and the physiological data from the individual to produce the PEMF in an intermediate target pattern. The method may also include a feedback loop for continually updating the PEMF emission pattern based on up-to-date physiological data from the individual so as to gradually or incrementally alter the physiological state of the individual. The method may also include the use of the feedback loop for recording of the physiological effect of various PEMF emission patterns on multiple individuals belonging to a subset of the population and determining, using aggregates of the recorded data, improved algorithms for generating more effective PEMF emission patterns for individuals belonging to the same subset.
    • 10. 发明申请
    • PEPTIDES
    • WO2018083505A1
    • 2018-05-11
    • PCT/GB2017/053350
    • 2017-11-07
    • IMMUNOCORE LIMITED
    • POWLESLAND, AlexCHILLAKURI, ChandramouliSANGANI, DhavalHOOD, GrahamGALFRE, Elena
    • C07K14/47A61K39/00
    • The present invention provides a peptide comprising, consisting essentially of or consisting of (i) the amino acid sequence KMPEAGEEQPQV (SEQ ID NO: 1); (ii) the amino acid sequence ISQTPGINL (SEQ ID NO: 2); or (iii) the amino acid sequence of SEQ ID NO: 1 or 2 with the exception of 1, 2 or 3 amino acid substitutions and/or 1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions, wherein the peptide forms a complex with a Major Histocompatibility Complex (MHC) molecule. Also provided are a complex of the peptide a Major Histocompatibility Complex (MHC) molecule, a nucleic acid molecule comprising a nucleic acid sequence encoding the peptide, a vector comprising such a nucleic acid sequence, a cell comprising such a vector and a binding moiety that binds the peptide.
    • (i)氨基酸序列KMPEAGEEQPQV(SEQ ID NO:1);和(ii)氨基酸序列KMPEAGEEQPQV(SEQ ID NO:1)。 (ii)氨基酸序列ISQTPGINL(SEQ ID NO:2); 或(iii)除了1,2或3个氨基酸取代和/或1,2或3个氨基酸插入和/或1,2或3个氨基酸之外的SEQ ID NO:1或2的氨基酸序列 其中该肽与主要组织相容性复合体(MHC)分子形成复合物。 还提供了肽主要组织相容性复合物(MHC)分子的复合物,包含编码肽的核酸序列的核酸分子,包含此类核酸序列的载体,包含此类载体的细胞和结合部分 结合肽。